Last viewed:
SRNE
Prices are updated after-hours
SRNE
|
$0.024
57K
|
Health Technology
(0.0% 1d)
(0.0% 1m)
(-94.0% 1y)
(0.0% 2d)
(-33.3% 3d)
(-39.4% 7d)
(33.5%
volume)
Earnings Calendar: 2023-02-20
Market Cap: $ 13,230,748
http://www.sorrentotherapeutics.com
Sec
Filling
|
Patents
| 310 employees
(US) Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
cancer
covid
antibody
t-cell
ceiling
add to watch list
Paper trade
email alert is off
Press-releases
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
Published: 2024-03-27
(Crawled : 13:00)
- globenewswire.com
SCLX
|
$0.8597
-4.48%
1.3M
|
| -22.52%
| O: -0.66%
H: 10.33%
C: 7.33%
SRNE
|
$0.024
57K
|
Health Technology
| 122.22%
| O: -11.11%
H: 12.5%
C: 0.0%
company
Virpax Pharmaceuticals Reports 2023 Year-End Results
Published: 2024-03-26
(Crawled : 20:00)
- biospace.com/
VRPX
|
$3.86
-4.46%
5.1K
|
| -8.83%
| O: -0.68%
H: 3.17%
C: 2.65%
SRNE
|
$0.024
57K
|
Health Technology
| 122.22%
| O: 11.11%
H: 0.0%
C: -10.0%
virpax
pharmaceuticals
results
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
Published: 2024-03-15
(Crawled : 13:00)
- globenewswire.com
SCLX
|
$0.8597
-4.48%
1.3M
|
| -15.83%
| O: 0.72%
H: 2.89%
C: -2.14%
SRNE
|
$0.024
57K
|
Health Technology
| 42.86%
| O: -7.14%
H: 46.15%
C: 38.46%
virpax
wholly
pharmaceuticals
agreement
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024
Published: 2024-03-02
(Crawled : 00:20)
- globenewswire.com
SRNE
|
$0.024
57K
|
Health Technology
| Email alert
Add to watchlist
SCLX
|
$0.8597
-4.48%
1.3M
|
| Email alert
Add to watchlist
company
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Published: 2024-02-27
(Crawled : 13:30)
- biospace.com/
VRPX
|
$3.86
-4.46%
5.1K
|
| 920.89%
| O: -14.39%
H: 7.35%
C: -0.24%
SRNE
|
$0.024
57K
|
Health Technology
| -28.57%
| O: 7.14%
H: 66.67%
C: -11.0%
virpax
pharmaceuticals
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement
Published: 2024-02-26
(Crawled : 22:00)
- globenewswire.com
SCLX
|
$0.8597
-4.48%
1.3M
|
| -43.48%
| O: 1.45%
H: 15.24%
C: 10.0%
SRNE
|
$0.024
57K
|
Health Technology
| -28.57%
| O: 7.14%
H: 66.67%
C: -11.0%
virpax
wholly
pharmaceuticals
agreement
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24
(Crawled : 17:00)
- prnewswire.com
PFE
A
|
$25.91
2.05%
22M
|
Health Technology
| -10.59%
| O: 0.39%
H: 0.82%
C: -0.74%
NVS
|
$94.285
1.85%
1.6M
|
Health Technology
| -13.6%
| O: 0.22%
H: 0.43%
C: -0.39%
SRNE
|
$0.024
57K
|
Health Technology
| -33.33%
| O: -63.33%
H: 263.64%
C: 127.27%
GILD
|
News
|
$66.45
0.44%
4.3M
|
Health Technology
| -15.83%
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL
|
$4.635
-3.44%
740K
|
Health Technology
| -11.96%
| O: -0.91%
H: 11.52%
C: 4.94%
drug
report
t-cell
global
therapy
market
Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
Published: 2024-01-08
(Crawled : 14:00)
- globenewswire.com
SCLX
|
$0.8597
-4.48%
1.3M
|
| -42.65%
| O: 3.82%
H: 5.76%
C: 1.04%
SRNE
|
$0.024
57K
|
Health Technology
| -82.38%
| O: -2.03%
H: 3.42%
C: -1.08%
company
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
Published: 2023-11-17
(Crawled : 17:00)
- biospace.com/
VRPX
|
$3.86
-4.46%
5.1K
|
| 388.18%
| O: 6.92%
H: 0.0%
C: -7.88%
SRNE
|
$0.024
57K
|
Health Technology
| -61.9%
| O: 0.0%
H: 14.29%
C: 3.05%
nasdaq
virpax
pharmaceuticals
UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure
Published: 2023-10-27
(Crawled : 20:00)
- globenewswire.com
SRNE
|
$0.024
57K
|
Health Technology
| Email alert
Add to watchlist
SCLX
|
$0.8597
-4.48%
1.3M
|
| Email alert
Add to watchlist
company
update
order
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount